Vidac Pharma Holding cooperation with Centroderm GMBH for its next Clinical Trial in Actinic Keratosis

August 15, 2023 08:28 PM AEST | By EIN Presswire

Google News:

Vidac Pharma Holding cooperation with Centroderm GMBH for its next Clinical Trial in Actinic Keratosis — Image source: EIN Presswire

Recent News

Fed Daly eyes fall for possible policy shift

Fifth Third Announces Three-Year, $20M Investment in North Nashville

Inogen Alliance Associate Awards: Environment Analyst Sustainability D...

New Zealand Construction Report 2025: Output to Contract by 1% Due to...

UK, August 15, 2023/EINPresswire.com/ -- Vidac Pharma is proud to announce that its next pre-Phase 3 Clinical trial on advanced Actinic Keratosis will be held in close collaboration with Centroderm Gmbh headed by Prof. Thomas Dirschka a world Key Opinion Leader in the dermatology field. The two parties are working together to establish the precise protocol of the trial which will address the more advanced cases of Actinic Keratosis with high proliferation profile which are the most prone to evolve into Squamous Cell Carcinoma a dangerous form of Cancer.

Prof Dirschka`s dermatological clinic possesses all the capacities to both select and treat those patients with potential high risk and declared “We are happy to work with Vidac Pharma which developed a completely new approach to Non-Melanoma Skin Cancer with potentially low side effect due to the specificity of their drug candidate”.
Prof. Herzberg Chairman of Vidac Pharma commented “Most of the lesions in Actinic Keratosis are not going to evolve on the spectrum to Squamous Cell Carcinoma. Our product aims to target those which have this dangerous potential and only those. In previous Phase 2B we observed exceptionally low side effects because of this specificity. We are very hopeful that this collaboration combining the exceptional capacities of Centroderm and Prof Dirschka research and our new approach to reverse the Warburg effect will help patients in the near future.”

Rehovot (Israel), London (UK) and Wuppertal (Germany)

About Vidac Pharma: Vidac Pharma Holdings Plc. London, is the holding company of Vidac Pharma Ltd. Rehovot. The Company is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases.

About Centroderm: CentroDerm GmbH headed by Prof. Thomas Dirschka and Dr. Lutz Schmitz is a specialized treatment facility in the field of dermatology with • a private dermatological practice • a surgical treatment facility with a high-end equipped dermatological surgery area • a dermatological laser center with twelve different state-of-the-art skin lasers • a dermato-histological laboratory • a molecular biology laboratory • a clinical study center.
www.centroderm.de

Disclaimer
The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.

Vidac Pharma Holding PLC
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
[email protected]
+972-54-4257381
+972 (0)779300647

Max Herzberg
Vidac pharma Holding Plc
+972 54-425-7381
email us here
Visit us on social media:
LinkedIn

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.